INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Age: 18 to75 years old                             │ Age: 18 to75 years old                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Failure of prior therapy (during or after          │ Failure of prior therapy (during or after          │     100 │
│ treatment) in patients who have received at least  │ treatment) in patients who have received at least  │         │
│ two prior chemotherapy regimens                    │ two prior chemotherapy regimens                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ECOG PS of 0-2                                     │ ECOG PS of 0-2                                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient received apatinib treatment regimen at     │ Patient received apatinib treatment regimen at     │     100 │
│ investigators' discretion                          │ investigators' discretion                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient has to voluntarily join the study and sign │ Patient has to voluntarily join the study and sign │     100 │
│ the Informed Consent Form for the study            │ the Informed Consent Form for the study            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy test (serum or urine) has to be          │ Pregnancy test (serum or urine) has to be          │     100 │
│ performed for woman of childbearing age within 7   │ performed for woman of childbearing age within 7   │         │
│ days before enrolment and the test result must be  │ days before enrolment and the test result must be  │         │
│ negative. They shall take appropriate methods for  │ negative. They shall take appropriate methods for  │         │
│ contraception during the study until the 8th week  │ contraception during the study until the 8th week  │         │
│ post the last administration of study drug. For    │ post the last administration of study drug. For    │         │
│ men, (previous surgical sterilization accepted),   │ men, (previous surgical sterilization accepted),   │         │
│ shall agree to take appropriate methods of         │ shall agree to take appropriate methods of         │         │
│ contraception during the study until the 8th week  │ contraception during the study until the 8th week  │         │
│ post the last administration of study drug         │ post the last administration of study drug         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Factors that could have an effect on oral          │ Factors that could have an effect on oral          │     100 │
│ medication (such as inability to swallow, chronic  │ medication (such as inability to swallow, chronic  │         │
│ diarrhea and intestinal obstruction)               │ diarrhea and intestinal obstruction)               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or lactating women                        │ Pregnant or lactating women                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other conditions regimented at investigators'      │ Other conditions regimented at investigators'      │     100 │
│ discretion                                         │ discretion                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with uncontrolled arterial hypertension   │ Subjects with poor-controlled arterial             │      87 │
│ (systolic blood pressure\> 140 mmHg and diastolic  │ hypertension (systolic blood pressure> 140 mmHg    │         │
│ blood pressure \> 90 mm Hg) despite standard       │ and diastolic blood pressure > 90 mm Hg) despite   │         │
│ medical management; Grade ≥ 2 coronary heart       │ standard medical management; Coronary heart        │         │
│ disease; Grade ≥ 2 arrhythmia (including QT        │ disease greater than ClassII; II-level arrhythmia  │         │
│ interval prolongation, for man \> 450 ms, for      │ (including QT interval prolongation, for man = 450 │         │
│ woman \> 470 ms), as well as Grade ≥ 2 cardiac     │ ms, for woman = 470 ms) together with Class II     │         │
│ dysfunction                                        │ cardiac dysfunction                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with high gastrointestinal bleeding risk, │ Subjects with high gastrointestinal bleeding risk, │      87 │
│ including the following conditions: presence of    │ including the following conditions: local active   │         │
│ active ulceration combined with a positive fecal   │ ulcer lesions with positive fecal occult blood     │         │
│ occult blood test (++);history of hematemesis and  │ test (++); history of black stool, or vomiting     │         │
│ melena within three months before enrollment;      │ blood in the past 3 months;unresected primary      │         │
│ unresected primary lesion in stomach with positive │ lesion in stomach with positive fecal occult blood │         │
│ fecal occult blood test (+), ulcerated gastric     │ test (+), ulcerated gastric carcinoma with massive │         │
│ carcinoma with massive alimentary tract bleeding   │ alimentary tract bleeding risk judged by PIs based │         │
│ risk judged by PIs based on gastric endoscopy      │ on gastric endoscopy result                        │         │
│ finding                                            │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Abnormal coagulation (INR\>1.5、APTT\>1.5 UNL),    │ Abnormal Coagulation (INR>1.5<U+3001>APTT>1.5      │      89 │
│ with tendency of bleeding                          │ UNL), with tendency of bleed                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ An expected survival of ≥ 3 months                 │ An expected survival of = 3 months                 │      97 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                 │ Age: 18 to75 years old                             │      36 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Biochemical tests results                         │ Associated with CNS (central nervous system)       │      40 │
│                                                   │ metastases                                         │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 75 Years                 │ Age: 18 to75 years old                             │      40 │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For results of blood routine test (without blood  │ Patient has to voluntarily join the study and sign │      41 │
│ transfusion within 14 days)                       │ the Informed Consent Form for the study            │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major organ function has to meet the following    │ Other conditions regimented at investigators'      │      43 │
│ criteria                                          │ discretion                                         │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HB ≥ 90g / L ANC ≥ 1.5 × 109 / L PLT ≥ 80 × 109 / │ ANC = 1.5 × 109 / L                                │      51 │
│ L                                                 │                                                    │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Bilirubin \<1.25 times the upper limit of normal  │ Serum Cr = 1 × ULN endogenous creatinine           │      56 │
│ (ULN) ALT and AST \<2.5 × ULN; liver metastases,  │ clearance>50ml/min (Cockcroft-Gault formula)       │         │
│ if any, the ALT and AST\<5 × ULN Serum Cr ≤ 1 ×   │                                                    │         │
│ ULN endogenous creatinine clearance\>50ml/min     │                                                    │         │
│ (Cockcroft-Gault formula)                         │                                                    │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pathologically diagnosed with advanced gastric    │ Pathologically diagnosed with advanced gastric     │      65 │
│ cancer (including adenocarcinoma of the           │ cancer (including adenocarcinoma of the            │         │
│ gastroesophageal junction)                        │ gastroesophageal junction) with measurable         │         │
│                                                   │ metastases outside the stomach (measuring = 10mm   │         │
│                                                   │ on spiral CT scan, satisfying the criteria in      │         │
│                                                   │ RECIST 1.1)                                        │         │
├───────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of central nervous system metastases     │ Associated with CNS (central nervous system)       │      76 │
│                                                   │ metastases                                         │         │
╘═══════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                     │   Score │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ HB ≥ 90g / L ANC ≥ 1.5 × 109 / L PLT ≥ 80 × 109 / │ HB = 90g / L                                      │      35 │
│ L                                                 │                                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Bilirubin \<1.25 times the upper limit of normal  │ Bilirubin <1.25 times the upper limit of normal   │      39 │
│ (ULN) ALT and AST \<2.5 × ULN; liver metastases,  │ (ULN)                                             │         │
│ if any, the ALT and AST\<5 × ULN Serum Cr ≤ 1 ×   │                                                   │         │
│ ULN endogenous creatinine clearance\>50ml/min     │                                                   │         │
│ (Cockcroft-Gault formula)                         │                                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ HB ≥ 90g / L ANC ≥ 1.5 × 109 / L PLT ≥ 80 × 109 / │ PLT = 80 × 109 / L                                │      49 │
│ L                                                 │                                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Bilirubin \<1.25 times the upper limit of normal  │ ALT and AST <2.5 × ULN; liver metastases, if any, │      50 │
│ (ULN) ALT and AST \<2.5 × ULN; liver metastases,  │ the ALT and AST<5 × ULN                           │         │
│ if any, the ALT and AST\<5 × ULN Serum Cr ≤ 1 ×   │                                                   │         │
│ ULN endogenous creatinine clearance\>50ml/min     │                                                   │         │
│ (Cockcroft-Gault formula)                         │                                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ HB ≥ 90g / L ANC ≥ 1.5 × 109 / L PLT ≥ 80 × 109 / │ ANC = 1.5 × 109 / L                               │      51 │
│ L                                                 │                                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Bilirubin \<1.25 times the upper limit of normal  │ Serum Cr = 1 × ULN endogenous creatinine          │      56 │
│ (ULN) ALT and AST \<2.5 × ULN; liver metastases,  │ clearance>50ml/min (Cockcroft-Gault formula)      │         │
│ if any, the ALT and AST\<5 × ULN Serum Cr ≤ 1 ×   │                                                   │         │
│ ULN endogenous creatinine clearance\>50ml/min     │                                                   │         │
│ (Cockcroft-Gault formula)                         │                                                   │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Pathologically diagnosed with advanced gastric    │ Pathologically diagnosed with advanced gastric    │      65 │
│ cancer (including adenocarcinoma of the           │ cancer (including adenocarcinoma of the           │         │
│ gastroesophageal junction)                        │ gastroesophageal junction) with measurable        │         │
│                                                   │ metastases outside the stomach (measuring = 10mm  │         │
│                                                   │ on spiral CT scan, satisfying the criteria in     │         │
│                                                   │ RECIST 1.1)                                       │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Presence of central nervous system metastases     │ Associated with CNS (central nervous system)      │      76 │
│                                                   │ metastases                                        │         │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 88
Average Levenshtein Ratio of individual lines: 70.96666666666667
OverAll Ratio: 79.48333333333333
